Taiwan has started a new era in hematopoietic stem cell transplantation (HSCT) in 2003. Since the first successful case of an unrelated cord blood transplantation (CBT) for major thalassemia was reported, our overall rate of succeed with CBT is 90%. It is the gleams of new hope to treat children for hematological malignancies or severe combined immunodeficiency. Bone marrow transplantation was limited by unmatched donors, either without the same tissue type or the unwillingness of the donor; as a result, the best opportunity for transplantation was mistimed. The CBT has provided the alternative of allogeneic HSCT to patients. However, the CBT is full of difficulties during the process, is limited by the cognitive development of the patient and is full of uncertainty of the result that brings exhaustion to the family of the patient. The teamwork of medical staffs intervening in the key moment is important for the team, for the family and for the patient. The corporation between the medical staffs could continue its service of the ”re-growth of new life”.